Geopolitical shifts in the Middle East are emerging as a primary pressure point for global markets, as US-led efforts to secure peace face internal and regional resistance. While Hamas has reaffirmed its commitment to demilitarize Gaza during meetings with Jared Kushner, Prime Minister Benjamin Netanyahu continues to resist the peace roadmap, a standoff now complicated by the emergence of a new trilateral defense pact between Pakistan, Saudi Arabia, and Türkiye. This realignment is heightening risk, keeping oil prices steady amidst ongoing Iran-related jitters and adding operational pressure to sectors like Japanese automakers, which are simultaneously navigating a strengthening yen. Against this backdrop of macro uncertainty—marked by liquidity concerns in bitcoin futures, a potential bull trap in the Nikkei 225, and positive sovereign performance in Thailand—corporate activity remains driven by strategic consolidation and sectoral resilience. The biotech sector is particularly active, evidenced by Hutchmed’s successful Phase III lung cancer trial and Sandoz’s acquisition of biosimilar rights from Shanghai Henlius. Meanwhile, the AI investment narrative is showing signs of maturation as capex anxiety eases, underscored by HIVE Digital’s significant $350 million GPU cloud contract, even as other firms, such as Rebel Creamery, illustrate the material impact of legal and intellectual property challenges following a $23.785 million judgment in favor of Van Leeuwen.